These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17472830)

  • 1. Management of access to branded psychotropic medications in private health plans.
    Hodgkin D; Horgan CM; Garnick DW; Len Merrick E; Volpe-Vartanian J
    Clin Ther; 2007 Feb; 29(2):371-80. PubMed ID: 17472830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
    Hodgkin D; Horgan CM; Creedon TB; Merrick EL; Stewart MT
    J Ment Health Policy Econ; 2015 Dec; 18(4):165-73. PubMed ID: 26729008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.
    Hodgkin D; Horgan CM; Quinn AE; Merrick EL; Stewart MT; Leslie LK
    Clin Ther; 2014 Dec; 36(12):2034-2046. PubMed ID: 25450473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of a three-tier formulary on antidepressant utilization and expenditures.
    Hodgkin D; Parks Thomas C; Simoni-Wastila L; Ritter GA; Lee S
    J Ment Health Policy Econ; 2008 Jun; 11(2):67-77. PubMed ID: 18509214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability of addiction medications in private health plans.
    Horgan CM; Reif S; Hodgkin D; Garnick DW; Merrick EL
    J Subst Abuse Treat; 2008 Mar; 34(2):147-56. PubMed ID: 17499959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs.
    Briesacher B; Kamal-Bahl S; Hochberg M; Orwig D; Kahler KH
    Arch Intern Med; 2004 Aug 9-23; 164(15):1679-84. PubMed ID: 15302639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoption of Cost Effectiveness-Driven Value-Based Formularies in Private Health Insurance from 2010 to 2013.
    Brouwer ED; Basu A; Yeung K
    Pharmacoeconomics; 2019 Oct; 37(10):1287-1300. PubMed ID: 31270747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating Medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders.
    Donohue JM; Frank RG
    Psychiatr Serv; 2007 Oct; 58(10):1285-91. PubMed ID: 17914004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective, long-term follow-up study of the effect of a three-tier prescription drug copayment system on pharmaceutical and other medical utilization and costs.
    Fairman KA; Motheral BR; Henderson RR
    Clin Ther; 2003 Dec; 25(12):3147-61; discussion 3144-6. PubMed ID: 14749153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.
    Aldridge AP; Kroutil LA; Cowell AJ; Reeves DB; Van Brunt DL
    Pharmacoeconomics; 2011 Jul; 29(7):621-35. PubMed ID: 21473655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increases in Medicare prescription drug plan costs attributable to psychotropic medications.
    Zivin K; McCammon RJ; Davis MM; Halasyamani LK; Kales HC
    Am J Geriatr Psychiatry; 2008 Aug; 16(8):674-85. PubMed ID: 18669946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to Addiction Pharmacotherapy in Private Health Plans.
    Reif S; Horgan CM; Hodgkin D; Matteucci AM; Creedon TB; Stewart MT
    J Subst Abuse Treat; 2016 Jul; 66():23-9. PubMed ID: 27211993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Medicaid prescription copayments on use of antipsychotics and other medications in patients with schizophrenia.
    Doshi JA; Li P; Desai S; Marcus SC
    J Med Econ; 2017 Dec; 20(12):1252-1260. PubMed ID: 28792299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consumers face higher costs as health plans seek to control drug spending.
    Mays GP; Hurley RE; Grossman JM
    Issue Brief Cent Stud Health Syst Change; 2001 Nov; (45):1-4. PubMed ID: 11865903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals With Chronic Disease.
    Nair KV; Wolfe P; Valuck RJ; McCollum MM; Ganther JM; Lewis SJ
    J Manag Care Spec Pharm; 2020 May; 26(5):575-585. PubMed ID: 32347176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Member satisfaction related to self-reported cost share and difficulty in obtaining prescription drugs in a university pharmacy benefit plan.
    Nau DP; Chi C; Mallya U; Kirking DM
    J Manag Care Pharm; 2007 Mar; 13(2):135-41. PubMed ID: 17330974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.